click enter text
concern growth dilut current outweigh accret strateg
valu ci stock today clear investor
question whether compani growth profil top-lin
net incom meaning dilut post acquisit slower growth
pbm esrx newco rev net incom histor
indic lt growth despit management expect top-lin
slow modestli indic pbm revenu growth need
post deal bottom line remain importantli note ci
earn target ep appear reason use
consensu leav potenti acceler management target upsid
intermedi term term strategi investor broadli
would prefer use add scale medicar medicaid
valu integr pbm medic offer gener well understood
host webcast et friday march review
thought invit alreadi inbox remind
follow slide attach start page
ci look oversold compar ci/esrx peer includ aet/cv
other take account pro forma busi mix appear ci
settl similar territori aet/cv valuat perspect
assum price-to-earnings ci ep esrx would leav blend
multipl newco indic potenti stock
pro-forma ep see potenti upsid deal
lower pt given uncertainti deal close lt growth
expect view evolv pt decreas
trade fundament data
upsid target
total debt total cap
float
path forward look ci manag engag investor
next sever week job highlight opportun drive
increment growth market share pbm segment post deal
increment news doj review time import pbm
pharma suppli chain newsflow sentiment
read-thru fairli broad concern
two pbm deal ci/esrx aet/cv could increas odd one
block optumrx like lose ci total script time
low margin contract mean ep impact
final debat specul around potenti reaction
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
report limit sole use client wolf research pleas refer disclosur section locat
end report analyst certif import disclosur disclosur
growth
growth profil top-lin net incom question post acquisit slower growth pbm
esrx newco rev net incom histor indic lt growth despit management expect
top-lin slow modestli bottom line remain
ci show stori growth market remain skeptic co hasnt meaning dilut growth profil go forward
earn target ep appear reason post analysi gotten much pushback
term strategi investor broadli would prefer use add scale medicar medicaid valu
integr pbm medic offer gener well understood
concern two pbm deal aet/cv could increas odd one block
optumrx like lose ci total script time low margin mean ep impact
go specul around potenti reaction remain player includ wba/hum/etc
compar ci/esrx peer includ aet/cv other take account busi mix appear ci settl
similar territori aet/cv valuat perspect
assum price-to-earnings ci ep esrx would leav blend multipl newco indic potenti
stock pro-forma ep
see ci earn power estim reason conserv greater potenti upsid downsid
look ci management engag investor next sever week job highlight opportun drive increment
growth market share pbm segment post deal
increment news doj review time
pbm pharma suppli chain newsflow sentiment
summari deal specif
deal specif million target price per ci share price closetarget dilut share equiti purchas deal specificationstarget takeout deal specificationsd impli fee etc impli fee use fund deal specificationstot deal equiti issuanc deal specificationsacquir price per share price closeacquir share dilut share estimatepro forma dilut share specificationsd impli fee specif appear reflect gener debt million retain synergi primarili rate deal cvs/aet guidanceincrement annual capital-expenditure assumedcom accret wr ci esrx adjust transit client
stare estim reflect assumpt portion tax reform benefit sustain
estimate would w/deal ex tax drain vs current ci target
accret compani teen guidanc potenti driven synergi ramp
adjust make esrx transit client
forma incom statement net adjust net adjust pre-taxcorpor interest transact adjust tax transact adjust forma adjust net forma share forma adjust wolf research stand-alone vs wolf research synergi accret consensu ci esrx adjust transit client
accret modestli higher use consensu estim ci given wr estim
consensu driven capit deploy share count assumpt
forma incom statement net adjust net adjust pre-taxcorpor interest transact adjust tax transact adjust forma adjust net forma share forma adjust consensu stand-alone vs consensu synergi accret wr ci consensu esrx adjust
note use esrx consensu estim without make adjust transit client
suggest accret would earn flat
note estim higher given increment cash flow avail delev repurchas
forma incom statement net adjust net adjust pre-taxcorpor interest transact adjust tax transact adjust forma adjust net forma share forma adjust wolf research stand-alone vs wolf research synergi accret consensu ci esrx adjust
similarli accret would approach adjust esrx estim
forma incom statement net adjust net adjust pre-taxcorpor interest transact adjust tax transact adjust forma adjust net forma share forma adjust consensu stand-alone vs consensu synergi ci under-perform month prior deal
total
total
ci view pharmaci pbm growth driver
greater choic transpar medic integr gener increas pbm valu client
accredo esrx specialti pharmaci drive improv adher outcom save
esrx recent acquir evicor medic manag busi dovetail ci exist
enabl pharmaci becom import contact point member
support therapi innov value-bas drug contract
lack natur share donor make hard everyon win
estim pbm market measur adjust script come outsid
larg pbm prime
donat share rest industri would add industri growth
two plan point top-lin growth unh/ci-esrx would seem industri growth
opportun would need acceler larg competitor share donor
adjust script market share
exposur ci
select catamaran exclus pbm year per catamaran
file account total revenu significantli lower margin busi
expect bring start bring certain servic inhous soon deal close possibl even
 management state callw built signific structur flexibl contract
assum busi grew past year would constitut total
optum rx revenu optum rx extern revenu
margin hit ep lose busi would
similarli script basi estim ci script total optum rx script
ctrx revenu optum rx optum rx optum rx extern optum rx extern total total optum rxci dilut contribut ep market clearli view pbm deterior asset
sell pbm esrx contract
announc partial-outsourc pbm
bring pharmaci benefit manag servic hous medco
announc partial-outsourc pbm catamaran
announc deal acquir aet
announc creat pbm ingeniorx
announc esrx deal almost certain bring member back
read-through rest manag
industri consolid like forc peer consid broader strateg move
read-through rest manag
learn two deal go sector time like complic
thing look heighten concern aet/cv
given ci like potenti buyer hum/wcg stock could see near-
term weak howev note ci primarili focus commerci wcg
primarili focus govern program thu combin esrx wouldnt preclud
surviv compani consolid includ one remain medicaid compani
ci-esrx deal like forc issu collabor blue compani
alreadi partner number blue medicaid side current set pbm
attempt provid servic blue
mco partner consolid note could put addit pressur
smaller medicaid compani competit standpoint howev perspect
ci-esrx combin would still lack medicaid capabl similarli aet/cv would still
subscal nation peer unh/antm medicaid segment
companycomm ladvmdcdpbmanalyticsdeliverymix posit health plan signific invest deliveri capabl within optum health plan busi impact cvs/aet recent announc pbm strategi unclear commerci busi rapidli grow adv platform healthagen busi gain traction icaid largest exchang plan ambit expand adv in-hous pbm capabl largest adv plan intern pbm deliveri asset underweight icaid commerci pbm capabl deliveri asset pharmaci minuteclin pure-play pbm scale differenti commerci busi mid-siz adv exposur strong busi pure-play pbm deliveri asset pure-play pbm limit deliveri focu post restructur pharmaci pharmaceut wholesal distribut current healthcar busi mixhealth planhealth deliveri busi mix score futur potenti
combinationcomm lmedadvmdcdpbmanalyticsdeliverymix scorecom standard other chase hc servic aet combo would strong health plan pbm asset potenti success deliveri importantli would scale cash compet go forward ci esrx -aet combo would combin solid health plan pbm asset would still lack medicaid deliveri forma care busi mix plan deliveri current state stand far ahead peer
bubbl size rel market cap
healthcarediversifiedmcospbm medicaid mco potenti state world have not
potenti combin
bubbl size rel market cap
ceo cordiani note deal go formal preview felt confid approv
highli confid multipl review get regulatori approv de minimi overlap
look franchis base tradit servic program
focu pass major medic pharmaci cost save onto client notabl
pbm regulatori spotlight februari council econom advisor paper drug price reform
wednesday captur benefit competit patient fda commission scott gottlieb
top three pbm control two-third market top three wholesal top five
pharmaci market concentr may prevent optim competit save may alway pass
along employ consum often see situat consolid firmsth pbm distributor
drugstoresteam payor use individu market power effect split monopoli rent
larg manufactur intermediari rather pass save garner competit patient
multipl assum sotp analysi
close price deal-announc
wr multipl assum trade premium
ci gd corp esrx earn assum non-pbm
discount growth
discount growth
discount growth
epsepsmultipl epsepsmultipl epsepsmultiplehealth healthnananananananananaoptum fair pro-formaaet-cv pro-formaci-esrx pro-formasum partsvalu analysi ep sotp valuat analysi ci esrx vs
epsepsmultipl epsepsmultipl epsepsmultiplehealth fair wr epssum partsvalu analysi epsci-esrx pro-formaunh consensu ep epsepsmultipl epsepsmultipl epsepsmultiplehealth healthnananananananananaoptum fair partsvalu analysi epsantm wr epsantm consensu epsci-esrx pro-forma comp sheet
note aet stand-alone price target shown aet blend price target assum deal approv
show debt ebitdar compani
manag comp sheetaetantmcicnchummohunhwcgcvsesrxwbacv pfci pfwolf ratingppopopppopopopppppnappstock price outstand cap valu dividend wr price-to-earnings price current stock wr wr wr wr wr wr ev ebitdar ev ebitdar multiplesev ebitdarpric question concern
given stock trade around merger coupl recent aet post deal trajectori
expect concern ci esrx could could range-bound investor get color time
probabl close
manag go better job explain opportun acceler
growth esrx pbm given updat revenu guidanc assum top-lin vs esrx
previou guidanc importantli though foot ci ep power target
current consensu net incom potenti leav acceler upsid cushion
believ synergi appear reason corpor synergi cigna
expect give back much pbm integr benefit custom time
deal de-lever ci rang annual potenti allow
 continu see government scale capabl main area need
given recent commentari doj fda pharmaci suppli chain gener pbm
particular addit second vertic transact mco pbm increas
likelihood one deal fail close
esrx pbm custom react particularli health plan custom compet ci
said current deal complet major pbm health plan would see
ci least threaten competit standpoint vs stand-alon health plan client
nfp blue provid own health plan
timelin ci migrat script optumrx esrx post deal close
put addit pressur consid strateg altern
vertic integr trend firmli place one compani move
aggress merg partner remain mco
